Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Established diagnosis of Waldenström macroglobulinemia (the 2nd Workshop on Waldenstrom's macroglobulinemia) or Lymphoplasmacytic lymphoma or Splenic Marginal Zone Lymphoma, needing a treatment~* Life expectancy \> 6 months~* Creatinine \< 200 µmol/l~* SGPT and SGOT \< 2x ULN~* A negative direct Coombs test~* Written informed consent~Exclusion Criteria:~* Past chemotherapy/radiotherapy/immunotherapy prior to the study for Waldenström macroglobulinemia~* Previous malignancy less than 5 years ago except carcinoma in situ of the cervix and non-melanoma skin cancer~* Positive HIV serology~* Active Hepatitis B or C~* Lactation/pregnancy~* Impossible good compliance with the study protocol~* Active infection not controlled~* Psychological condition hampering understanding of the study~* Transformation into large B cell lymphoma~* Peripheral neuropathy \> grade II

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
- 2 (Type: ACTIVE_COMPARATOR): Fludarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).